Literature DB >> 20419344

Epidemiology of neuroendocrine cancers in an Australian population.

Colin Luke1, Timothy Price, Amanda Townsend, Christos Karapetis, Dusan Kotasek, Nimit Singhal, Elizabeth Tracey, David Roder.   

Abstract

OBJECTIVE: The aim was to explore incidence, mortality and case survivals for invasive neuroendocrine cancers in an Australian population and consider cancer control implications.
METHODS: Directly age-standardised incidence and mortality rates were investigated from 1980 to 2006, plus disease-specific survivals.
RESULTS: Annual incidence per 100,000 increased from 1.7 in 1980-1989 to 3.3 in 2000-2006. A corresponding mortality increase was not observed, although numbers of deaths were low, reducing statistical power. Increases in incidence affected both sexes and were more evident for female lung, large bowel (excluding appendix), and unknown primary site. Common sites were lung (25.9%), large bowel (23.3%) (40.9% were appendix), small intestine (20.6%), unknown primary (15.0%), pancreas (6.5%), and stomach (3.7%). Site distribution did not vary by sex (p = 0.260). Younger ages at diagnosis applied for lung (p = 0.002) and appendix (p < 0.001) and older ages for small intestine (p < 0.001) and unknown primary site (p < 0.001). Five-year survival was 68.5% for all sites combined, with secular increases (p < 0.001). After adjusting for age and diagnostic period, survivals were higher for appendix and lower for unknown primary site, pancreas, and colon (excluding appendix).
CONCLUSIONS: Incidence rates are increasing. Research is needed into possible aetiological factors for lung and large-bowel sites, including tobacco smoking, and excess body weight and lack of exercise, respectively; and Crohn's disease as a possible precursor condition.

Entities:  

Mesh:

Year:  2010        PMID: 20419344     DOI: 10.1007/s10552-010-9519-4

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  6 in total

1.  Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry.

Authors:  Adele Caldarella; Emanuele Crocetti; Eugenio Paci
Journal:  Pathol Oncol Res       Date:  2011-04-09       Impact factor: 3.201

2.  Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry.

Authors:  Jagannath Palepu; Shailesh V Shrikhande; Debanshu Bhaduri; Rajiv C Shah; Bhawna Sirohi; Verushka Chhabra; Puneet Dhar; Regulagedda Sastry; Sadiq Sikora
Journal:  Indian J Gastroenterol       Date:  2018-02-19

Review 3.  Neuroendocrine Neoplasms of the Small Bowel and Pancreas.

Authors:  Ashley Kieran Clift; Mark Kidd; Lisa Bodei; Christos Toumpanakis; Richard P Baum; Kjell Oberg; Irvin M Modlin; Andrea Frilling
Journal:  Neuroendocrinology       Date:  2019-09-27       Impact factor: 5.135

4.  Clinical Profiles and Survival Outcomes of Patients With Well-Differentiated Neuroendocrine Tumors at a Health Network in New South Wales, Australia: Retrospective Study.

Authors:  Jocelyn Reeders; Vivek Ashoka Menon; Anita Mani; Mathew George
Journal:  JMIR Cancer       Date:  2019-11-20

5.  Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand.

Authors:  Matthew J McGuinness; Braden Woodhouse; Christopher Harmston; Kate Parker; Nicole Kramer; Michael Findlay; Cristin Print; Arend Merrie; Ben Lawrence
Journal:  ANZ J Surg       Date:  2022-06-28       Impact factor: 2.025

6.  Dose escalation of an Evans blue-modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors.

Authors:  Qingxing Liu; Yuejuan Cheng; Jie Zang; Huimin Sui; Hao Wang; Orit Jacobson; Zhaohui Zhu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-12       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.